GLP-1 receptors and is resistant to degradation by dipeptidyl peptidase-4 (DPP-4), has been developed as a once-weekly formulation, 7–10 and is approved for use in  patients with type 2 diabetes. Incorporation of this drug into a matrix of poly-(D,L-lactic-co-glycolic acid), extends its release and allows for gradual delivery at controlled rates. 11 Once released, exenatide is renally excreted.  Exenatide once weekly has a median half-life of 2 weeks and reaches steady-state concentrations in 6–10 weeks. 9,12  Concentrations of fasting plasma glucose improve within 2 weeks from start of treatment. 9 Liraglutide is a GLP-1 receptor agonist that is approved  for once-daily use in patients with type 2 diabetes.13–18 This